|
Viral impact on autoimmune T cells |
5R21AI164732-02 |
|
NIAID |
2022 |
|
Use of use of dimethyl fumarate for targeting autoimmunity in type 1 diabetes |
5R21AI166368-02 |
|
NIAID |
2022 |
|
UC San Diego RAPID Faculty Development Program in Infectious Diseases |
5R25AI147376-03 |
|
NIAID |
2022 |
|
Oral autoantigen therapy for the treatment of Multiple Sclerosis |
5R43AI155401-02 |
|
NIAID |
2022 |
|
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects |
5R44AI122574-06 |
|
NIAID |
2022 |
|
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy |
5R44AI125060-04 |
|
NIAID |
2022 |
|
Immunotherapy of MRSA Osteomyelitis |
5R44AI155309-02 |
|
NIAID |
2022 |
|
A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic |
5R44AI157081-02 |
|
NIAID |
2022 |
|
Targeting professional APCs using Fasciola hepatica FABP to suppresses inflammation |
5SC1AI155439-03 |
|
NIAID |
2022 |
|
Treating Brain Swelling in Pediatric Cerebral Malaria |
5U01AI126610-06 |
|
NIAID |
2022 |